Cellectar Biosciences 13G Filing Shows Balyasny Asset Management Reports 9.99% Stake In Co As Of June 30, 2026, Holding 798,382 Shares And Warrants
- SEC Filing
Read original at benzingaStocks · News reference
Cellectar Biosciences Announces Publication Of Results From Phase 1 Dose-Escalation Study Evaluating Iopofosine I 131 In Combination With Low-Dose Dexamethasone In 31 Patients With Heavily Pretreated R/R MM
Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in Relapsed/Refractory Multiple MyelomaPublication Supports Continued Development of Iopofosine I 131 as a Novel TargetedRadiotherapeutic Across
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 15, 2026, 11:33 AM
- Checked
- Jul 15, 2026, 11:33 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Cellectar Biosciences 13G Filing Shows StemPoint Capital Reports 9.99% Stake In Co As Of June 30, 2026, Holding 845,740 Shares Including Pre-Funded Warrants
- SEC Filing
Read original at benzingaCellectar Biosciences 13G Filing Shows SilverArc Capital Reports 9.99% Stake In Co As Of June 30, 2026, Holding 851,285 Shares And Warrants
Read original at benzingaCellectar Biosciences Q2 2026 Earnings Call Transcript
On Thursday, Cellectar Biosciences (NASDAQ:CLRB) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For
Read original at benzinga